Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | LATS1 | O95835 | 2/20 | 0.42 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.42 |
| ▸ | AXL | P30530 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.40 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30324482 | 1.00 | KDM4E (0.50) | KDM4EMAPTSMN1; SMN2AURKAPARP1 | |
| SCHEMBL9386690 | 0.85 | KDM4E (0.40) | KDM4EMAPTSMN1; SMN2AURKAPARP1 | |
| SCHEMBL4560911 | 0.82 | AURKA (0.47) | KDM4EMAPTSMN1; SMN2AURKAPARP1 | |
| SCHEMBL23107328 | 0.80 | AURKA (0.46) | MAPTSMN1; SMN2AURKAPARP1NPC1 | |
| SCHEMBL8324572 | 0.80 | AURKA (0.46) | SMN1; SMN2AURKAPARP1NPC1HSP90AA1 | |
| SCHEMBL8324581 | 0.80 | AURKA (0.46) | KDM4EMAPTSMN1; SMN2AURKAPARP1 | |
| SCHEMBL857106 | 0.80 | AXL (0.47) | KDM4EMAPTSMN1; SMN2AURKAPARP1 | |
| SCHEMBL28329874 | 0.80 | AXL (0.47) | KDM4EMAPTSMN1; SMN2AURKAPARP1 | |
| SCHEMBL21115235 | 0.80 | AURKA (0.46) | KDM4EMAPTSMN1; SMN2AURKAPARP1 | |
| SCHEMBL8327130 | 0.79 | AURKA (0.44) | KDM4EMAPTSMN1; SMN2AURKAPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | JANSSEN PHARMACEUTICA NV (BE) | 2025-07-31 | — | — | US | disclosed |
| US-20230123856-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | TENAYA THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-20 | — | — | US | disclosed |
| WO-2022184152-A1 | FUSED RING SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-09-09 | — | — | WO | disclosed |
| WO-2021072487-A1 | SULFONAMIDE COMPOUNDS AND THE USE THEREOF IN THE TREATMENT OF CANCER | TroBio Therapeutics Pty Ltd (AU) | 2021-04-22 | — | — | WO | disclosed |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-04-26 | — | — | US | disclosed |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2016-06-23 | — | — | US | disclosed |
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2015-10-15 | — | — | US | disclosed |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | PLEXXIKON INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100137362-A1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| US-20100137362-A1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-06-03 | — | — | US | disclosed |
| WO-2010005528-A2 | PYRROLOPYRIDINE CARBOXYLIC ACID DERIVATIVES | IRONWOOD PHARMACEUTICALS INCORPORATED (US) | 2010-01-14 | — | — | WO | disclosed |
| EP-0509974-B1 | Pyrrolo[2,3-b]pyridines having therapeutic activity and a process for the preparation thereof | ASTRA AB (SE) | 1999-01-13 | — | — | EP | disclosed |
| US-5439917-A | Phenyl-pyrrolo(2,3-b)pyridine antisecretory agent of gastric acid; adenosine triphosphatase enzyme inhibitor | AKTIEBOLAGET ASTRA (SE) | 1995-08-08 | — | — | US | disclosed |
| EP-0580616-A1 | NEW ACTIVE COMPOUNDS | Astra Aktiebolag (SE) | 1994-02-02 | — | — | EP | disclosed |
| EP-0509974-A1 | Pyrrolo[2,3-b]pyridines having therapeutic activity and a process for the preparation thereof | Astra Aktiebolag (SE) | 1992-10-21 | — | — | EP | disclosed |
| WO-1992017477-A1 | NEW ACTIVE COMPOUNDS | AKTIEBOLAGET ASTRA (SE) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249118-A1 | protein kinase modulators such as Propane-1-sulfonic acid [2,4-difluoro-3-(5-ethoxy-1H-pyrrolo[1,3-b]pyridine-3-carbonyl)-phenyl]-amide, used to regulate signal transduction cascades, involved in the control of physiological functions including cellular growth and proliferation; anticarcinogenic agents | MAP4K1, MAP4K2, MAP3K1 | KDM4E 2005/4885MAPT 4171/4885SMN1; SMN2 3233/4885 |
| US-20220332713-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | KDM4E 2437/4885MAPT 2516/4885SMN1; SMN2 3418/4885 |
| US-20160031868-A1 | BENZIMIDAZOLONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | KDM4E 209/4885MAPT 1994/4885SMN1; SMN2 3186/4885 |
| US-20180111929-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KDM4E 2029/4885MAPT 2203/4885SMN1; SMN2 1839/4885 |
| US-20250243194-A1 | ANTAGONIST OF ADENOSINE RECEPTORS | ADORA2B, ADORA2A, ADORA1 | KDM4E 3478/4885MAPT 4767/4885SMN1; SMN2 3476/4885 |
| US-20150290205-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KDM4E 2029/4885MAPT 2203/4885SMN1; SMN2 1839/4885 |
| US-20160176865-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KDM4E 2029/4885MAPT 2203/4885SMN1; SMN2 1839/4885 |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | CDK7, CDK6, CDK3 | KDM4E 2788/4885MAPT 800/4885SMN1; SMN2 3322/4885 |
| US-20100256365-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, MAP3K13, MAP3K8 | KDM4E 2029/4885MAPT 2203/4885SMN1; SMN2 1839/4885 |
| US-20100137362-A1 | HETEROCYCLIC HYDRAZIDE COMPOUND AND PESTICIDAL USE OF THE SAME | ACHE, CAT, DNPH1 | KDM4E 2297/4885MAPT 4261/4885SMN1; SMN2 2564/4885 |
| US-20230123856-A1 | 5-FLUORONICOTINAMIDE DERIVATIVES AND USES THEREOF | SLC28A1, SLC5A1, SLC9A5 | KDM4E 2006/4885MAPT 1698/4885SMN1; SMN2 684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.